Alumis Inc
ALMS
Company Profile
Business description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Contact
280 East Grand Avenue
South San FranciscoCA94080
USAT: +1 650 231-6625
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
224
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,980.50 | 31.60 | -0.35% |
| CAC 40 | 8,112.57 | 89.51 | -1.09% |
| DAX 40 | 24,338.63 | 324.98 | -1.32% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,233.07 | 43.88 | -0.43% |
| HKSE | 26,393.71 | 232.57 | -0.87% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 62,713.65 | 120.19 | -0.19% |
| NZX 50 Index | 13,175.13 | 95.48 | -0.72% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,744.40 | 36.40 | -0.41% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |